The article reflects on noninvasive evaluation of liver fibrosis in patients with chronic hepatitis C. It is said that the ideal marker for liver fibrosis need to be specific to fibrosis of the liver, not influenced by co-morbidities. It is also said that the risk-benefit ratio of liver biopsy is insufficient to maintain it as a firstline procedure.